Statera Biopharma, Inc.
STAB
$0.00
$0.000.00%
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Net Income | -218.40% | -339.50% | -523.47% | -742.17% | -185.70% |
| Total Depreciation and Amortization | 288.55% | 13,524.32% | 21,958.82% | 28,300.00% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 392.83% | 494.88% | 709.73% | 918.38% | 654.22% |
| Change in Net Operating Assets | 794.14% | 258.71% | 1,034.48% | 3,011.96% | -444.56% |
| Cash from Operations | 31.12% | -170.67% | -282.68% | -454.75% | -126.40% |
| Capital Expenditure | -16.05% | -414.51% | -1,192.31% | -1,806.25% | -1,250.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -100.00% | 2,337.37% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -100.76% | 2,701.19% | 93,579.86% | 138,892.78% | 202,440.30% |
| Total Debt Issued | -96.62% | -96.64% | -- | -- | 12,779.69% |
| Total Debt Repaid | -10,241.35% | -- | -- | -- | -- |
| Issuance of Common Stock | 25.63% | 136.97% | 136.09% | 25.64% | 10.42% |
| Repurchase of Common Stock | 97.72% | 97.72% | 98.86% | -- | -606.18% |
| Issuance of Preferred Stock | -- | -- | -46.15% | 29.21% | 167.40% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 100.00% | -434.74% | -434.58% | -- |
| Cash from Financing | -108.93% | -107.20% | 103.27% | 269.24% | 121.80% |
| Foreign Exchange rate Adjustments | 4,165.00% | 56.54% | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -198.66% | -212.88% | -99.80% | 955.52% | 4,410.29% |